Melodiol Global Health Limited engages in the development, cultivation, and distribution of recreational and medical cannabis products in Europe, Canada, Australia, and the Asia Pacific. It is involved in the development and commercialisation of nutraceutical products; and medical supplies business. The company was formerly known as Creso Pharma Limited and changed its name to Melodiol Global Health Limited in June 2023. Melodiol Global Health Limited was incorporated in 2015 and is headquartered in Nedlands, Australia.

Melodiol Global Health Ltd.

Mr. Boaz  Wachtel M.A., M.D., MBA

Co-Founder & Non-Executive Chairman

Mr. William  Lay B.Com.

Group CEO, MD & Director

Mr. Christopher  Grundy BCom, FCA, FCIS, GAICD

Chief Financial Officer

Ms. Micheline  MacKay B.Sc., M.Sc., P.M.P.

Executive Director

Dr. Gian  Trepp

Commercial & Marketing Director

Mr. Mitchel  Fleming

Managing Director of Halucenex

Brett  Ayers

Managing Director of Impactive

Mr. Winton William Willesee C.P.A., GAICD, MAICD, MCom

Joint Company Secretary

Hon. Brian  Walker

Strategic Consultant & Chair of Scientific Advisory Committee

Melodiol Global Health Ltd. (ME1) Stock Analysis, Discussion Forum and Financial Metrics - ASX Exchange

Melodiol Global Health Ltd. (ME1) Earnings Report Date and History | ASX

ME1's next earnings is on February 26, 2025 (After Market Close)

When is the earnings report for ME1?

ME1 Earnings History

ME1 Stock Discussion Forum and Message Board

News for ASX: ME1